Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2026-05-15 Major Shareholding Noti…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 93% confidence The document is a TR-1 form notification under UK/EU transparency rules detailing an acquisition of voting rights and threshold crossing (from 8.405% to 7.771%). This is a Major Shareholding Notification as per definition.
2026-05-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 form under the UK Disclosure and Transparency Rules reporting a threshold crossing for a major shareholder (James Robert Kight reaching 3.32574% voting rights). It details ISIN, shareholding percentages, dates, and the structure of a standard major shareholding notification. This aligns exactly with the “Major Shareholding Notification” category (MRQ).
2026-05-15 English
Positive Ox-1 tox data in addiction programme
Regulatory Filings Classification · 90% confidence The document is an RNS press release by TheraCryf plc providing a clinical progress update on its Ox-1 blocker preclinical toxicology programme. It is not an earnings release, formal financial report, or management change notice, but a general corporate announcement distributed via the London Stock Exchange’s RNS system. Therefore it falls under Regulatory Filings (RNS).
2026-05-14 English
Investor Webinar
Regulatory Filings Classification · 85% confidence The document is an RNS press release announcing an upcoming investor webinar for TheraCryf plc, with logistical details and a link to register. There is no attached financial report, transcript, or presentation deck, nor is it an Earnings Release, Board change, Dividend notice, or other specific category. It does not fit any specialized category, so it falls under the general regulatory filings (RNS) fallback.
2026-04-21 English
Successful GMP Manufacture Advances Ox-1 to Clinic
Regulatory Filings Classification · 82% confidence The document is a corporate RNS announcement from TheraCryf plc providing an operational update on the successful GMP manufacture of their lead asset for clinical use. It is not a financial report (10-K, IR, ER), not an AGM/EGM notice, not regulatory filings for governance or capital changes, nor a call transcript, investor presentation, or legal update. It fits as a general regulatory announcement via RNS, falling into the fallback Regulatory Filings (RNS) category.
2026-04-20 English
Non-Binding Proposal to Acquire TheraCryf’s Assets
M&A Activity Classification · 91% confidence The document is an RNS announcement stating that the company has received and rejected a non‐binding indicative proposal to acquire its lead neuropsychiatry assets. It deals with acquisition proposals and asset takeover discussions, which falls squarely under M&A Activity (Code: TAR).
2026-04-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.